Choose semaglutide if: Cost is the primary barrier, you have cardiovascular disease and need the SELECT trial CV evidence behind your treatment, or you respond well to GLP-1 therapy alone
Christensen S, Robinson K, Thomas S, Williams DR
At the same time, the available studies are still early, so GLP-1s should not be viewed as a breast cancer treatment outside a clinical trial
Recent clinical results suggest that GLP-1RAs slow down the progression of PD, therefore the search for and improvement of drugs targeted by GLP-1R should be continued [63]
Despite these challenges, the potential of BPC 157 as a therapeutic agent remains significant
Alzheimers Disease Facts and Figures